Federico Mensa

4.2k total citations · 1 hit paper
88 papers, 1.9k citations indexed

About

Federico Mensa is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Federico Mensa has authored 88 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hepatology, 51 papers in Infectious Diseases and 37 papers in Epidemiology. Recurrent topics in Federico Mensa's work include Hepatitis C virus research (77 papers), HIV/AIDS drug development and treatment (44 papers) and Liver Disease Diagnosis and Treatment (28 papers). Federico Mensa is often cited by papers focused on Hepatitis C virus research (77 papers), HIV/AIDS drug development and treatment (44 papers) and Liver Disease Diagnosis and Treatment (28 papers). Federico Mensa collaborates with scholars based in United States, Germany and France. Federico Mensa's co-authors include Jens Kort, Edward Gane, Franco Felizarta, Stanislas Pol, Armen Asatryan, Teresa I. Ng, Preethi Krishnan, Matthew P. Kosloski, David R. Nelson and Chih‐Wei Lin and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of the American College of Cardiology.

In The Last Decade

Federico Mensa

86 papers receiving 1.8k citations

Hit Papers

Glecaprevir and Pibrentasvir in Patients with HCV and Sev... 2017 2026 2020 2023 2017 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
    2017 271 citations Edward Gane, Eric Lawitz et al. New England Journal of Medicine profile →

Peers

Federico Mensa
Janice Wahl United States
Daniel E. Cohen United States
Anu Osinusi United States
Nathalie Adda United States
Ziv Ben Ari Israel
Franco Felizarta United States
Sandra Lovell United States
Sarah Arterburn United States
J.A. Carrión Spain
Sonia Rodríguez‐Nóvoa Spain
Janice Wahl United States
Federico Mensa
Citations per year, relative to Federico Mensa Federico Mensa (= 1×) peers Janice Wahl

Countries citing papers authored by Federico Mensa

Since Specialization
Citations

This map shows the geographic impact of Federico Mensa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Mensa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Mensa more than expected).

Fields of papers citing papers by Federico Mensa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Mensa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Mensa. The network helps show where Federico Mensa may publish in the future.

Co-authorship network of co-authors of Federico Mensa

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Mensa. A scholar is included among the top collaborators of Federico Mensa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Mensa. Federico Mensa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Türeci, Özlem, et al.. (2024). Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. Human Vaccines & Immunotherapeutics. 20(1). 2315659–2315659. 9 indexed citations
3.
Pather, Shanti, et al.. (2023). Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era. Expert Review of Vaccines. 22(1). 650–661. 11 indexed citations
4.
Kosloski, Matthew P., et al.. (2023). Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. Clinical and Translational Science. 16(4). 593–605. 4 indexed citations
5.
Foster, Graham R., Tarik Asselah, Lei Yang, et al.. (2019). Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 14(1). e0208506–e0208506. 26 indexed citations
6.
7.
Kosloski, Matthew P., Daniel A.J. Bow, Ryota Kikuchi, et al.. (2019). Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir. Journal of Pharmacology and Experimental Therapeutics. 370(2). 278–287. 16 indexed citations
8.
Flamm, Steven L., K. Rajender Reddy, Neddie Zadeikis, et al.. (2018). Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clinical Gastroenterology and Hepatology. 17(3). 527–535.e6. 17 indexed citations
9.
Kwo, Paul Y., Peter J.H. Jones, Joseph Gathe, et al.. (2018). SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C. Journal of the American College of Cardiology. 71(11). A1763–A1763. 1 indexed citations
10.
Puoti, Massimo, Graham R. Foster, Stanley Wang, et al.. (2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology. 69(2). 293–300. 112 indexed citations
11.
Asselah, Tarik, Samuel S. Lee, Betty Yao, et al.. (2018). Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. ˜The œLancet. Gastroenterology & hepatology. 4(1). 45–51. 43 indexed citations
12.
Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure. Hepatology. 67(4). 1253–1260. 105 indexed citations
13.
Gane, Edward, Eric Lawitz, David Pugatch, et al.. (2017). Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. New England Journal of Medicine. 377(15). 1448–1455. 271 indexed citations breakdown →
14.
Zeuzem, Stefan, Parvez Mantry, Vincent Soriano, et al.. (2016). Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology & Hepatology. 28(8). 923–926. 1 indexed citations
15.
Asselah, Tarik, Christophe Hézode, Neddie Zadeikis, et al.. (2016). ENDURANCE-4: Efficacy and Safety of ABT-493/ABT-530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection. Hepatology. 63. 7 indexed citations
16.
Gane, Edward, Fred Poordad, Stanley Wang, et al.. (2016). High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 151(4). 651–659.e1. 72 indexed citations
17.
Asselah, Tarik, Stefan Zeuzem, Vincent Soriano, et al.. (2015). ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE. 10(12). e0144004–e0144004. 4 indexed citations
18.
Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2014). Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. Antimicrobial Agents and Chemotherapy. 59(2). 1282–1291. 8 indexed citations
19.
Giaquinto, Carlo, Gabriel Anabwani, Cornelia Feiterna‐Sperling, et al.. (2014). Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1–infected Children and Adolescents. The Pediatric Infectious Disease Journal. 33(7). e173–e179. 5 indexed citations
20.
Zeuzem, Stefan, Tarik Asselah, Peter Angus, et al.. (2013). Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results. Antiviral Therapy. 18(8). 1015–1019. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janice Wahl Breakdown of academic impact, for papers by Daniel E. Cohen Breakdown of academic impact, for papers by Anu Osinusi Breakdown of academic impact, for papers by Nathalie Adda Breakdown of academic impact, for papers by Ziv Ben Ari Breakdown of academic impact, for papers by Franco Felizarta Breakdown of academic impact, for papers by Sandra Lovell Breakdown of academic impact, for papers by Sarah Arterburn Breakdown of academic impact, for papers by J.A. Carrión Breakdown of academic impact, for papers by Sonia Rodríguez‐Nóvoa
Rankless by CCL
2026